Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antisense HIV-1 therapy - Enzo Therapeutics

Drug Profile

Antisense HIV-1 therapy - Enzo Therapeutics

Alternative Names: HGTV-43; StealthVector®HGTV43™

Latest Information Update: 09 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzo Therapeutics
  • Class Antisense oligonucleotides; Antivirals; Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 09 Sep 2016 Phase-II clinical trials in HIV-1 infections in USA (Parenteral) before September 2016 (Enzo Biochem pipeline, September 2016)
  • 07 Jan 2016 Phase-I/II development for HIV-1 infections is ongoing in USA
  • 21 Sep 2015 Phase-I/II development for HIV-1 infections is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top